Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 178Lung Neoplasms 56Neoplasms 14NSCLC 11Brain Neoplasms 11Neoplasm Metastasis 10Carcinoma 9Meningeal Carcinomatosis 6Colorectal Neoplasms 5Bronchial Neoplasms 5Thoracic Neoplasms 4Respiratory Tract Neoplasms 3Respiratory Tract Diseases 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms by Site 3Lung Diseases 3Carcinoma, Squamous Cell 3Breast Neoplasms 3Adenocarcinoma of Lung 3Adenocarcinoma 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumor 2Prostatic Neoplasms 2Noonan Syndrome 2Non Small Cell Lung Cancer Metastatic 2

Interventions

toripalimab 1pelcitoclax 1osimertinib 1Pemetrexed 1Paclitaxel 1Injections 1Erlotinib Hydrochloride 1Docetaxel 1Cisplatin 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
EGFR Positive Non-small Cell Lung Cancer × osimertinib × Clear all
NCT04001777 2025-10-01

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Ascentage Pharma Group Inc.

Phase 1 Active not recruiting
80 enrolled
Thoracic

EGFR Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡